Summary: A new study reveals that GIPR drugs act through two anatomically distinct brain regions. Activating GIPR in the brainstem directly suppresses appetite. Conversely, blocking GIPR in the hypothalamus removes an inhibitory “brake” that normally restricts the brainstem’s capacity to process satiety signals.
By removing this hypothalamic brake, GIPR antagonists significantly enhance the weight-loss efficacy of GLP-1 receptor agonists like semaglutide and emerging amylin receptor therapies like cagrilintide. These findings provide a clear mechanistic blueprint for designing next-generation combination obesity therapeutics.
Key Facts
- Anatomical Circuit Separation: GIPR agonists suppress appetite by directly stimulating receptors in the brainstem, whereas GIPR antagonists promote weight loss by blocking receptors in the hypothalamus.
- Release of the Hypothalamic Brake: Blocking GIPR in the hypothalamus disables a regulatory mechanism that limits the brainstem’s sensitivity to fullness signals, effectively gating how the hindbrain responds to metabolic inputs.
- Synergy with GLP-1 and Amylin Therapies: Removing the hypothalamic GIPR brake sensitizes the brain to multiple classes of satiety-inducing drugs, boosting the efficacy of both GLP-1 receptor agonists (e.g., Wegovy) and amylin receptor agonists (e.g., cagrilintide).
- Mechanistic Proof for Clinical Pipeline: The findings explain the clinical success of dual-action therapies like MariTide (GIPR antagonist/GLP-1 agonist) and tirzepatide (Mounjaro/Zepbound), while offering a rational framework to combine GIPR blockade with emerging multi-incretin candidates like CagriSema.
- Genetic Region-Specific Deletion: The Cambridge team isolated these distinct circuit mechanisms using mouse models with cell-type and region-specific knockout of GIPR in either the brainstem or the hypothalamus.
Source: University of Cambridge
Cambridge scientists have solved the mystery of why both stimulating and blocking a particular ‘switch’ in the brain can help people lose weight – findings which could help boost the effectiveness of obesity drugs.
Published today in Nature Metabolism, the study in mice shows that the answer lies in where the switch is located: stimulating the switch in the brainstem suppresses appetite, while the same effect can be achieved by blocking the switch in the hypothalamus.
More than a billion people worldwide are living with obesity, which increases the risk of diseases such as 2 diabetes, cardiovascular disease and cancer. Weight loss can help mitigate these complications, but losing weight through diet and exercise alone can prove challenging.
In the past few years, a new generation of weight loss drugs has emerged that target particular receptors in the brain, reducing appetite and leading to weight loss, as well as helping control blood sugar levels. Several of these, such as Wegovy and Ozempic, work by stimulating a protein ‘switch’ known as the glucagon-like peptide 1 receptor (GLP-1R).
Other weight loss drugs act on both this receptor and a second one, the glucose-dependent insulinotropic polypeptide receptor (GIPR). However, some of these drugs, such as Mounjaro and Zepbound, stimulate GIPR, while others, such as MariTide, block it. Why these opposite actions have the same result has puzzled scientists.
Now, researchers at the Institute of Metabolic Science, University of Cambridge, have used mice to solve the puzzle, showing that the two different types of GIPR drugs act on distinct regions of the brain – but also that they can boost weight loss when combined with certain GLP-1-based weight-loss drugs.
The team used genetically engineered mice and selectively removed GIPR from different parts of the brain to see which regions were responsible for the effects of the obesity drugs. One group of mice lacked GIPR in the brainstem – the area at the base of the brain, just above the spinal cord, involved in appetite and nausea. A second group lacked GIPR in the hypothalamus, a major centre controlling hunger and body weight. The third, control group were normal, unmodified mice.
The researchers then treated these mice with various combinations of a GIPR agonist (which activates the receptor), a GIPR antagonist (which blocks the receptor) and a GLP-1 drug, and measured food intake, body weight, fat mass, glucose control and brain activity.
By comparing the responses of normal mice with mice lacking GIPR in different brain areas, they showed that GIPR agonists act on the brainstem to suppress appetite and reduce weight.
They then showed that GIPR antagonists help weight loss by acting on this receptor, but in the hypothalamus, where they release a ‘brake’ that otherwise limits the brainstem’s ability to respond to signals telling us we are full. Blocking GIPR also appeared to boost the effect of emerging new drugs targeting the amylin receptor, suggesting that GIPR antagonists could potentially be used to strengthen several types of anti-obesity medicines.
The findings explain why drugs such as MariTide, currently in phase 3 clinical trials, which combines GIPR antagonism with GLP-1 receptor agonism, are effective, and suggests how to design even better combination therapies.
Dr Jo Lewis, the study’s first author from the Institute of Metabolic Science at the University of Cambridge, said: “Understanding which brain circuits respond to these medications – and how they do so – could help us design better drugs that produce more weight loss with fewer side effects, and which might work in combination with other obesity medicines to even greater effect.
“Our work also strengthens the idea that the brain is central to obesity treatment. Obesity drugs are not acting simply on the gut or pancreas. Instead, they have important effects on specific, identifiable brain circuits that regulate appetite and food intake.”
Funding: The research was funded by the Medical Research Council and Wellcome.
Key Questions Answered:
A: In classical pharmacology, activating a receptor and blocking it produce opposite biological outcomes. However, clinical trials showed that both GIPR agonists (like tirzepatide) and GIPR antagonists (like MariTide) effectively reduce body weight when paired with GLP-1 drugs, confusing researchers about the underlying mechanism.
A: The hypothalamus acts as a central gatekeeper for long-term energy balance. GIPR signaling in the hypothalamus acts as a natural “brake” on the brainstem’s satiety centers. Blocking hypothalamic GIPR releases this brake, making brainstem circuits vastly more responsive to fullness signals triggered by GLP-1 or amylin drugs.
A: It proves that obesity medications work via specific, hierarchical brain circuits rather than simple peripheral effects on the gut or pancreas. This provides a clear roadmap to engineer combination therapies that achieve higher weight loss with lower doses and fewer gastrointestinal side effects.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this neuropharmacology and weight loss research news
Author: Craig Brierley
Source: University of Cambridge
Contact: Craig Brierley – University of Cambridge
Image: The image is credited to Neuroscience News
Original Research: Open access.
“Distinct brain regions mediate regulation of food intake in response to GIPR agonism and antagonism” by Jo Edward Lewis, Mireia Montaner, Danae Nuzzaci, Paula-Peace James-Okoro, Norio Harada, Nobuya Inagaki, W. Scott Dodson, Patrick J. Knerr, Jonathan D. Douros, Fiona Mary Gribble & Frank Reimann. Nature Metabolism
DOI:10.1038/s42255-026-01575-z
Abstract
Distinct brain regions mediate regulation of food intake in response to GIPR agonism and antagonism
The development of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has been a landmark moment in the treatment of type 2 diabetes and obesity.
However, for reasons that are incompletely understood, in preclinical and clinical studies, adding either a GIPR agonist or GIPR antagonist to GLP-1R agonism causes additional weight loss. Here we show that distinct brain regions mediate the appetite-suppressing effects of GIPR agonists and the synergistic weight loss effects conferred by GIPR antagonists.
We knock out Gipr in either the area postrema (AP) or hypothalamus of mice (GiprAP-KO and Giprhypo-KO, respectively) and compare body weight and food intake responses to GIPR agonists and antagonists, alone and in combination with the GLP-1R agonist liraglutide. GiprAP-KO mice exhibit partial protection against diet-induced obesity, reduced responsiveness to the appetite-suppressing effects of acyl-GIP and a reduced ability of acyl-GIP to prevent avoidance triggered by peptide YY.
Weight loss effects of liraglutide are comparable in GiprAP-KO and control mice, and the co-administration of a GIPR antagonist peptide causes similar additional weight loss in both groups. Giprhypo-KO mice, by contrast, exhibit normal appetite suppression by acyl-GIP but enhanced weight loss on liraglutide compared with control mice. Giprhypo-KO also abolishes the synergistic effect of a GIPR antagonist when combined with liraglutide—an effect that is not mediated by nucleus tractus solitarius preproglucagon neurons. GIPR antagonism and Giprhypo-KO also sensitise to cagrilintide-induced weight loss.
Overall, our results suggest that the AP is responsible for the appetite-suppressing effects of GIPR agonism but that GIP receptors in the hypothalamus underlie the ability of GIPR antagonism to enhance the weight loss effects of GLP-1R and amylin receptor agonists.
